Merck and Daiichi’s first ADC attempt is knocked back, while Geron gets its inaugural approval.

Meanwhile, Bristol’s other competition in this disease looks set to come from China.

Breyanzi and Imdelltra head up May’s approvals, while camrelizumab’s CRL is a lowlight.

Meanwhile, Lilly gets in on the next-gen KRAS action.

But the group’s attempt to join Janux at the high altar of masking technology falls flat.

Amid doubts about early data with FG-3246, the group is scathing about its rivals.

The group reckons big pharma is eyeing KIF18A inhibition, but for now there are just a handful of players.

Blockade of CCR8 has quietly emerged as a hot oncology target, especially for anti-PD-(L)1 MAb combinations.